GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Days Sales Outstanding

Biosyent (Biosyent) Days Sales Outstanding : 33.86 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Biosyent Days Sales Outstanding?

Biosyent's average Accounts Receivable for the three months ended in Dec. 2023 was $2.29 Mil. Biosyent's Revenue for the three months ended in Dec. 2023 was $6.17 Mil. Hence, Biosyent's Days Sales Outstanding for the three months ended in Dec. 2023 was 33.86.

The historical rank and industry rank for Biosyent's Days Sales Outstanding or its related term are showing as below:

BIOYF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.95   Med: 32.56   Max: 36.64
Current: 36.64

During the past 13 years, Biosyent's highest Days Sales Outstanding was 36.64. The lowest was 17.95. And the median was 32.56.

BIOYF's Days Sales Outstanding is ranked better than
83.02% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs BIOYF: 36.64

Biosyent's Days Sales Outstanding declined from Dec. 2022 (35.08) to Dec. 2023 (33.86).


Biosyent Days Sales Outstanding Historical Data

The historical data trend for Biosyent's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Days Sales Outstanding Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.49 27.49 26.09 35.53 32.09

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.08 43.16 38.95 36.05 33.86

Competitive Comparison of Biosyent's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biosyent's Days Sales Outstanding falls into.



Biosyent Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biosyent's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.054 + 2.086) / 2 ) / 23.547*365
=2.07 / 23.547*365
=32.09

Biosyent's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.491 + 2.086) / 2 ) / 6.167*365 / 4
=2.2885 / 6.167*365 / 4
=33.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Biosyent Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biosyent's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020